2023 World Conference on Lung Cancer (Posters)-EP10.01. Efficacy of Intraventricular Chemotherapy with Pemetrexed for Leptomeningeal Metastasis from Lung Adenocarcinoma: A Retrospective Study

EP10.01. Efficacy of Intraventricular Chemotherapy with Pemetrexed for Leptomeningeal Metastasis from Lung Adenocarcinoma: A Retrospective Study - PDF(Slides)

Back to course

Pdf Summary

Intraventricular chemotherapy with pemetrexed has shown promising results in the treatment of leptomeningeal metastasis (LM) from lung adenocarcinoma, according to a retrospective study. LM is a serious complication of lung cancer with limited treatment options and poor prognosis. The study aimed to evaluate the efficacy and safety of intraventricular chemotherapy with pemetrexed in patients with LM.<br /><br />The study enrolled patients with lung adenocarcinoma and confirmed LM, aged 18-75 years. The primary endpoints of the study were progression-free survival (PFS) and overall survival (OS), while secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety.<br /><br />The chemotherapy regimen consisted of intraventricular administration of pemetrexed and dexamethasone twice a week during the induction phase, followed by monthly maintenance. The median PFS was 6.8 months, and the median OS was not reached. Subgroup analysis showed that the higher dose of pemetrexed (50mg) had a longer median PFS than the lower dose (30mg). Patients with an ECOG performance status of 2-3 had a longer median PFS compared to those with a status of 4.<br /><br />The overall adverse event rate was 65%, with mild and transient effects such as nausea, vomiting, seizures, and myelosuppression. The study concluded that intraventricular chemotherapy with pemetrexed demonstrated excellent results in patients with lung adenocarcinoma and LM, with acceptable toxicity.<br /><br />The authors acknowledge the study participants, their families, and caregivers, as well as the study team members and staff involved in the trial.<br /><br />In summary, this study suggests that intraventricular chemotherapy with pemetrexed may be an effective and safe treatment option for patients with LM from lung adenocarcinoma. Further research is needed to validate these findings and optimize treatment strategies.

Asset Subtitle

ShenCun Fang

Meta Tag

Speaker ShenCun Fang

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

intraventricular chemotherapy

pemetrexed

leptomeningeal metastasis

lung adenocarcinoma

retrospective study

efficacy

safety

progression-free survival

overall survival

chemotherapy regimen